CD47 and neoplasm: In a syngeneic orthotopic mouse glioma model, these CAR-MACs effectively suppressed tumor growth, with a combinatory approach with CD47 blockade further enhancing their therapeutic efficacy.78 While these innovative approaches remain in the preclinical phase, advancing them to clinical trials is essential.